ZA200206688B - Esmolol formulation. - Google Patents

Esmolol formulation. Download PDF

Info

Publication number: ZA200206688B
Authority: ZA; South Africa
Prior art keywords: pharmaceutical composition; osmotic; hydrochloride; esmolol; aqueous
Prior art date: 2001-01-12

Application number

ZA200206688A

Other languages

English (en)

Inventor

Jie Liu

Satish K Pejaver

George Owoo

Original Assignee

Baxter Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-12

Filing date

2002-08-21

Publication date

2004-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056065&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200206688(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-21 Application filed by Baxter Int filed Critical Baxter Int

2004-03-10 Publication of ZA200206688B publication Critical patent/ZA200206688B/en

Links

239000000203 mixture Substances 0.000 title claims description 48
238000009472 formulation Methods 0.000 title description 28
229960003745 esmolol Drugs 0.000 title description 13
AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 title description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 claims description 16
229960001015 esmolol hydrochloride Drugs 0.000 claims description 16
239000006172 buffering agent Substances 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
238000000034 method Methods 0.000 claims description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
239000011780 sodium chloride Substances 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
239000008121 dextrose Substances 0.000 claims description 6
230000000747 cardiac effect Effects 0.000 claims description 5
238000007911 parenteral administration Methods 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims description 3
239000001103 potassium chloride Substances 0.000 claims description 3
235000011164 potassium chloride Nutrition 0.000 claims description 3
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
229940022663 acetate Drugs 0.000 claims description 2
229940050390 benzoate Drugs 0.000 claims description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
239000001110 calcium chloride Substances 0.000 claims description 2
229910001628 calcium chloride Inorganic materials 0.000 claims description 2
235000011148 calcium chloride Nutrition 0.000 claims description 2
229940001468 citrate Drugs 0.000 claims description 2
229940050410 gluconate Drugs 0.000 claims description 2
229930195712 glutamate Natural products 0.000 claims description 2
229940049906 glutamate Drugs 0.000 claims description 2
229940001447 lactate Drugs 0.000 claims description 2
GXLJZLBKWSJXFP-UHFFFAOYSA-N phenyl propanoate;hydrochloride Chemical compound Cl.CCC(=O)OC1=CC=CC=C1 GXLJZLBKWSJXFP-UHFFFAOYSA-N 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
239000001540 sodium lactate Substances 0.000 claims description 2
229940005581 sodium lactate Drugs 0.000 claims description 2
235000011088 sodium lactate Nutrition 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 claims 1
239000000243 solution Substances 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
239000003708 ampul Substances 0.000 description 8
238000004659 sterilization and disinfection Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000000047 product Substances 0.000 description 7
230000001954 sterilising effect Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 6
239000004800 polyvinyl chloride Substances 0.000 description 6
239000008215 water for injection Substances 0.000 description 6
229920000915 polyvinyl chloride Polymers 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 4
239000002876 beta blocker Substances 0.000 description 4
229940097320 beta blocking agent Drugs 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000011049 filling Methods 0.000 description 4
239000012362 glacial acetic acid Substances 0.000 description 4
235000017281 sodium acetate Nutrition 0.000 description 4
238000013329 compounding Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000011169 microbiological contamination Methods 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000002002 slurry Substances 0.000 description 3
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
230000036512 infertility Effects 0.000 description 2
238000007689 inspection Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000010979 pH adjustment Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000013618 particulate matter Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
229940087562 sodium acetate trihydrate Drugs 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
238000012371 Aseptic Filling Methods 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
238000012865 aseptic processing Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000011018 current good manufacturing practice Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
229920002457 flexible plastic Polymers 0.000 description 1
239000011888 foil Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000004492 methyl ester group Chemical group 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001012 protector Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009517 secondary packaging Methods 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200206688A 2001-01-12 2002-08-21 Esmolol formulation. ZA200206688B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/759,547 US6310094B1 (en)	2001-01-12	2001-01-12	Ready-to-use esmolol solution

Publications (1)

Publication Number	Publication Date
ZA200206688B true ZA200206688B (en)	2004-03-10

Family

ID=25056065

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200206688A ZA200206688B (en)	2001-01-12	2002-08-21	Esmolol formulation.

Country Status (8)

Country	Link
US (2)	US6310094B1 (pt)
EP (1)	EP1738756A3 (pt)
JP (2)	JP5778384B2 (pt)
KR (1)	KR100889090B1 (pt)
CN (2)	CN1981739B (pt)
AR (1)	AR098013A2 (pt)
PT (1)	PT1368019E (pt)
ZA (1)	ZA200206688B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6310094B1 (en) *	2001-01-12	2001-10-30	Baxter International Inc.	Ready-to-use esmolol solution
JP2005504090A (ja)	2001-09-26	2005-02-10	バクスター・インターナショナル・インコーポレイテッド	分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US7112340B2 (en) *	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
CN1303987C (zh) *	2004-11-19	2007-03-14	陈庆财	注射用盐酸艾司洛尔冻干粉针剂及其制备方法
EP1906973A2 (en) *	2005-06-14	2008-04-09	Baxter International Inc.	Pharmaceutical formulations for minimizing drug-drug interactions
CA2628630A1 (en) *	2005-11-15	2007-05-24	Baxter International Inc.	Compositions of lipoxygenase inhibitors
WO2008080047A2 (en) *	2006-12-23	2008-07-03	Baxter International Inc.	Magnetic separation of fine particles from compositions
CN105746492A (zh)	2007-02-17	2016-07-13	哈佛学院董事会	用于进行组织保存的组合物以及方法
US8426467B2 (en)	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US20080293814A1 (en)	2007-05-22	2008-11-27	Deepak Tiwari	Concentrate esmolol
US8722736B2 (en)	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
JP2011512350A (ja) *	2008-02-15	2011-04-21	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	血液代用溶液
JP2011512351A (ja) *	2008-02-15	2011-04-21	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	心臓手術のための心停止液
ES2443159T3 (es)	2009-09-22	2014-02-18	Vlife Sciences Technologies Pvt Ltd.	Formulación tópica para úlceras del pie diabético
CA2825311A1 (en)	2011-01-27	2012-08-02	Baxter International Inc.	Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension
KR20140019334A (ko) *	2011-01-27	2014-02-14	백스터 인터내셔널 인코포레이티드	심장 질환의 치료와 관련된 정맥 자극을 조절하기 위한 (s)-에스모롤의 용도
US8242158B1 (en)	2012-01-04	2012-08-14	Hospira, Inc.	Dexmedetomidine premix formulation
AU2013249034B2 (en) *	2012-04-19	2016-04-28	C. R. Bard, Inc.	Infusates with enhanced pH stability under ethylene oxide sterilization
PL2846776T3 (pl) *	2012-05-10	2020-09-21	Aop Orphan Pharmaceuticals Ag	Pozajelitowy preparat Esmololu
MX2014015269A (es) *	2012-06-27	2015-02-20	Takeda Pharmaceutical	Preparaciones liquidas de aminas y acidos organicos estabilizados por sales.
US8835505B1 (en) *	2013-03-15	2014-09-16	Welgrace Research Group	Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
CN106729661A (zh) *	2016-12-02	2017-05-31	广东天普生化医药股份有限公司	人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物
WO2018140894A1 (en)	2017-01-30	2018-08-02	Nevakar, Inc	Norepinephrine compositions and methods therefor
US11380145B2 (en)	2019-02-14	2022-07-05	Oshkosh Corporation	Systems and methods for a virtual refuse vehicle
US20220218740A1 (en) *	2020-10-25	2022-07-14	Vaporworks Nursing Anesthesia Inc.	Opioid-free compositions for anesthesiological applications and related methods and systems

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0179808B1 (en) *	1984-04-09	1991-10-30	The Du Pont Merck Pharmaceutical Company	Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders
US4857552A (en) *	1988-06-08	1989-08-15	E. I. Du Pont De Nemours And Co.	Stable pharmaceutical composition
US6310094B1 (en) *	2001-01-12	2001-10-30	Baxter International Inc.	Ready-to-use esmolol solution
TWI277414B (en) *	2001-01-12	2007-04-01	Baxter Int	Esmolol formulation

2001
- 2001-01-12 US US09/759,547 patent/US6310094B1/en not_active Expired - Lifetime
- 2001-10-30 US US10/016,260 patent/US6528540B2/en not_active Expired - Lifetime
2002
- 2002-01-02 KR KR1020027011900A patent/KR100889090B1/ko active IP Right Grant
- 2002-01-02 CN CN2006101685054A patent/CN1981739B/zh not_active Expired - Lifetime
- 2002-01-02 PT PT02736473T patent/PT1368019E/pt unknown
- 2002-01-02 EP EP06016319A patent/EP1738756A3/en not_active Withdrawn
- 2002-01-02 CN CNA2005101184817A patent/CN1775207A/zh active Pending
- 2002-08-21 ZA ZA200206688A patent/ZA200206688B/en unknown
2009
- 2009-11-02 JP JP2009252474A patent/JP5778384B2/ja not_active Expired - Lifetime
2013
- 2013-05-15 JP JP2013102769A patent/JP2013151572A/ja active Pending
2014
- 2014-10-14 AR ARP140103809A patent/AR098013A2/es unknown

Also Published As

Publication number	Publication date
JP2013151572A (ja)	2013-08-08
JP2010024249A (ja)	2010-02-04
CN1775207A (zh)	2006-05-24
US6310094B1 (en)	2001-10-30
US20020147239A1 (en)	2002-10-10
US6528540B2 (en)	2003-03-04
CN1981739A (zh)	2007-06-20
EP1738756A2 (en)	2007-01-03
JP5778384B2 (ja)	2015-09-16
PT1368019E (pt)	2007-01-31
CN1981739B (zh)	2010-12-08
KR100889090B1 (ko)	2009-03-17
AR098013A2 (es)	2016-04-27
KR20020093839A (ko)	2002-12-16
EP1738756A3 (en)	2009-01-14